BioPharma Services is Pleased to Announce Dr. Janice Faulknor as Their New Dedicated Medical Director

TORONTO--(BUSINESS WIRE)--BioPharma Services Inc. (BPSI) is pleased to announce that Dr. Janice Faulknor has joined the company in the role of Medical Director and as a member of the Executive Team. Dr. Faulknor brings to BioPharma extensive knowledge and experience in the area of Phase I and Bioequivalency Clinical Trials and will provide medical leadership and support to the organization.

"I am very pleased to be joining the BioPharma family and to support their growth strategies in Phase 1 and complex early stage clinical research."
Dr. Faulknor has held senior medical roles within Pharmaceutical Contract Research Organizations, responsible for Phase 1, SAD-MAD, and Bioequivalence studies, at CRO organizations including INC Research. She is well known and respected for her abilities to assist sponsors achieve their clinical research goals. BPSI's Chief Executive Officer, Renzo DiCarlo stated: "We are extremely pleased to have Dr. Faulknor on board as our Medical Director. She brings a wealth of experience to BioPharma in Phase 1 clinical trials."

Dr. Esmat Dessouki will continue to provide medical expertise to the organization at the Board of Directors and as Chief Medical Officer and is well known as a leader in anticoagulant research. Dr Faulknor stated: "I am very pleased to be joining the BioPharma family and to support their growth strategies in Phase 1 and complex early stage clinical research."

About BioPharma Services Inc.:

BioPharma Services Inc. is a physician-owned, physician-run, US FDA-inspected, UK MHRA-inspected, and Health Canada-inspected International Contract Research Organization (CRO) which specializes in the conduct of Phase I/IIa clinical trials, including FIM trials, BE studies and Bioanalysis, for international pharmaceutical and biotech companies from the US, Canada, Australia and Europe. The company currently has a modern 174-bed clinical facility based in Toronto, Canada, and a new 72-bed clinical facility in Columbia, Missouri. It is privately held, and it is headquartered in Toronto, Canada.

For press release and other company information, visit BioPharma Services Inc.'s web site at www.biopharmaservices.com

Contacts

BioPharma Services Inc.
Ilan T. Rose, 1-416-747-8484
V.P. Business Development
[email protected]

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.